<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>form8k801exh999-16.txt
<DESCRIPTION>EXH 00 - PR RE STUDY HOLD
<TEXT>


                                   EXHIBIT 99

<PAGE>


CEL-SCI CORPORATION
                                                         Contact: Gavin de Windt
                                                      Investor Relations Manager
                                                             Phone: 703 506-9460
                                              Email address:gdewindt@cel-sci.com

           CEL-SCI REPORTS CLINICAL HOLD ON HEAD AND NECK CANCER STUDY

VIENNA,  VA, September 26, 2016 - CEL-SCI  Corporation (NYSE MKT: CVM) announced
today  that  it  has  received  verbal  notice  from  the  U.S.  Food  and  Drug
Administration (FDA) that its Multikine (Leukocyte  Interleukin Injection) Phase
3 clinical  trial in  advanced  primary  head and neck cancer has been placed on
clinical  hold.  Pursuant to this  communication  from FDA,  patients  currently
receiving  study  treatments  can  continue to receive  treatment,  and patients
already  enrolled in the study will  continue to be  followed.  CEL-SCI was also
told to  expect  a  formal  letter  from the FDA  within  30 days and will  work
diligently  with the FDA to obtain the release of the clinical  hold.  The study
currently has about 926 patients enrolled.

About CEL-SCI Corporation

CEL-SCI's  work is focused on finding the best way to activate the immune system
to fight cancer and infectious diseases. Its lead investigational immunotherapy,
Multikine (Leukocyte  Interleukin,  Injection),  is currently being studied in a
pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients
with squamous cell carcinoma of the head and neck. If the study endpoint,  which
is an improvement in overall survival of the subjects treated with the Multikine
treatment  regimen  plus the  current  standard  of care  (SOC) as  compared  to
subjects treated with the current SOC only, is satisfied, the study results will
be used to support  applications  that the Company plans to submit to regulatory
agencies in order to seek commercial  marketing approvals for Multikine in major
markets around the world. Additional clinical indications for Multikine that are
being  investigated  include  the  treatment  of cervical  dysplasia  in HIV/HPV
co-infected  women, and the treatment of peri-anal warts in HIV/HPV  co-infected
men and women.  A Phase 1 trial of the former  indication  has been completed at
the University of Maryland.  The latter  indication is now in a Phase 1 trial at
UCSF.  CEL-SCI has issued patents on Multikine  from the US,  Europe,  China and
Japan.

CEL-SCI is also developing its pre-clinical  L.E.A.P.S.  (Ligand Epitope Antigen
Presentation   System)  technology  for  the  potential  treatment  of  pandemic
influenza in hospitalized  patients and as a potential vaccine for the treatment
of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans" and  "expects,"  and
similar expressions,  are intended to identify forward-looking  statements. Such
statements  are  subject  to risks and  uncertainties  that could  cause  actual
results to differ  materially from those projected.  Factors that could cause or
contribute to such differences  include,  an inability to duplicate the clinical
results  demonstrated in clinical studies,  timely  development of any potential
products  that  can be  shown  to be safe  and  effective,  receiving  necessary
regulatory  approvals,  difficulties  in  manufacturing  any  of  the  Company's
potential  products,  inability  to raise  the  necessary  capital  and the risk

<PAGE>

factors set forth from time to time in CEL-SCI  Corporation's  filings  with the
Securities and Exchange  Commission,  including but not limited to its report on
Form 10-K for the year ended  September  30,  2015.  The Company  undertakes  no
obligation   to  publicly   release   the  result  of  any   revision  to  these
forward-looking   statements  which  may  be  made  to  reflect  the  events  or
circumstances   after  the  date  hereof  or  to  reflect  the   occurrence   of
unanticipated events.

*Multikine is the trademark that CEL-SCI has registered for this investigational
therapy,  and this  proprietary name is subject to FDA review in connection with
the Company's future anticipated  regulatory submission for approval.  Multikine
has not been licensed or approved for sale, barter or exchange by the FDA or any
other  regulatory  agency.  Similarly,  its  safety  or  efficacy  have not been
established for any use. Moreover,  no definitive  conclusions can be drawn from
the  early-phase,  clinical-trials  data involving the  investigational  therapy
Multikine (Leukocyte Interleukin,  Injection). Further research is required, and
early-phase  clinical  trial  results  must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is currently in progress.





</TEXT>
</DOCUMENT>
